利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.017 秒)

    HUMANIZED ANTIBODIES AGAINST GLOBO H AND USES THEREOF IN CANCER TREATMENTS
    1.
    发明申请
    HUMANIZED ANTIBODIES AGAINST GLOBO H AND USES THEREOF IN CANCER TREATMENTS 审中-公开

    公开(公告)号：US20200048365A1

    公开(公告)日：2020-02-13

    申请号：US15988875

    申请日：2018-05-24

    申请人： Development Center for Biotechnology

    发明人： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

    IPC分类号： C07K16/34

    摘要： A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

    Humanized antibodies against Globo H and uses thereof in cancer treatments
    2.
    发明授权
    Humanized antibodies against Globo H and uses thereof in cancer treatments 有权

    公开(公告)号：US10781265B2

    公开(公告)日：2020-09-22

    申请号：US15988875

    申请日：2018-05-24

    申请人： Development Center for Biotechnology

    发明人： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

    IPC分类号： C07K16/34

    摘要： A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

    Anti-granulysin antibodies and methods of use thereof
    5.
    发明授权
    Anti-granulysin antibodies and methods of use thereof 有权
    抗颗粒溶素抗体及其使用方法

    公开(公告)号：US09428575B2

    公开(公告)日：2016-08-30

    申请号：US14145583

    申请日：2013-12-31

    申请人： Development Center for Biotechnology ,  DCB-USA LLC

    发明人： Jiann-Shiun Lai ,  Hung-Ling Wang ,  Chao-Yang Huang ,  Ying-Yung Lok ,  Yuan-Tsong Chen ,  Woan-Eng Chan ,  Chih-Yung Hu

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

    摘要： An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

    摘要翻译： 能够结合到颗粒溶素的R64至R113的表位区并能够中和颗粒溶素活性的抗颗粒溶素抗体或其scFv或Fab片段。 抗体可以含有选自SEQ ID NO：82至SEQ ID NO：195的序列的序列，或者抗体可以含有选自SEQ ID NO：39至SEQ ID NO：76的序列的序列。 抗体可以是单克隆抗体。 用于治疗或预防不需要的免疫应答障碍的方法包括向有需要的受试者施用有效量的能够中和颗粒溶素活性的抗颗粒溶素抗体。 不想要的免疫应答障碍可以是SJS，TEN或GVHD。

    ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY
    6.
    发明申请
    ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY 有权
    ALPHA-ENOLASE特异性抗体及其在癌症治疗中的使用方法

    公开(公告)号：US20150183884A1

    公开(公告)日：2015-07-02

    申请号：US14142186

    申请日：2013-12-27

    申请人： NATIONAL HEALTH RESEARCH INSTITUTES ,  DEVELOPMENT CENTER FOR BIOTECHNOLOGY

    发明人： Shih-Chong Tsai ,  Neng-Yao Shih ,  Ta-Tung Yuan ,  Ko-Jiunn Liu ,  Shih-Chi Tseng ,  Chih-Yung Hu ,  Hsin-Yun Wang ,  Li-Tzong Chen

    IPC分类号： C07K16/40 ,  G01N33/574

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/988

    摘要： The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

    摘要翻译： 本发明公开了可以结合肽的抗人α-烯醇酶（ENO1）抗体，其包含氨基酸序列296FD QDDWGAWQKF TA309（SEQ ID：＃9）和/或326K RIAKAVN EK S336（SEQ ID＃＃10 ）的人类ENO1蛋白（GenBank：AAH50642.1）具有良好的结合活性（结合亲和力约为2.19×10 -10 mol / L），并且具有显着的抑制多种肿瘤细胞侵袭和肿瘤转移的能力 。 公认的本发明的肽和抗体可用于已经报道表达细胞表面ENO1的癌症的诊断，预后和治疗，所述癌症包括肺，乳腺，胰腺，肝脏，结肠直肠癌，前列腺癌和实体瘤。